← Back to patent-cliff list
Fostroxacitabine bralpamide
Tier C — Watch / tradeFostroxacitabine bralpamide
Medivir AB
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DNA
Indications (approved)：Hepatocellular carcinoma, Cholangiocarcinoma, Liver cancer
Regional status
US
-
EU
Phase II
2018-09-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fostroxacitabine bralpamide?
Approved indications include: Hepatocellular carcinoma, Cholangiocarcinoma, Liver cancer.
When does the Fostroxacitabine bralpamide patent expire?
No public expiry year is available for Fostroxacitabine bralpamide yet; this page updates once verified.
How do I get a quote for Fostroxacitabine bralpamide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08